Cargando…
Screening of selective histone deacetylase inhibitors by proteochemometric modeling
BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/ https://www.ncbi.nlm.nih.gov/pubmed/22913517 http://dx.doi.org/10.1186/1471-2105-13-212 |
_version_ | 1782255469932314624 |
---|---|
author | Wu, Dingfeng Huang, Qi Zhang, Yida Zhang, Qingchen Liu, Qi Gao, Jun Cao, Zhiwei Zhu, Ruixin |
author_facet | Wu, Dingfeng Huang, Qi Zhang, Yida Zhang, Qingchen Liu, Qi Gao, Jun Cao, Zhiwei Zhu, Ruixin |
author_sort | Wu, Dingfeng |
collection | PubMed |
description | BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study. RESULTS: The results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R(2) = 0.9897, Q(test)(2) = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors. CONCLUSIONS: Our best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect. |
format | Online Article Text |
id | pubmed-3542186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35421862013-01-11 Screening of selective histone deacetylase inhibitors by proteochemometric modeling Wu, Dingfeng Huang, Qi Zhang, Yida Zhang, Qingchen Liu, Qi Gao, Jun Cao, Zhiwei Zhu, Ruixin BMC Bioinformatics Research Article BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study. RESULTS: The results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R(2) = 0.9897, Q(test)(2) = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors. CONCLUSIONS: Our best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect. BioMed Central 2012-08-22 /pmc/articles/PMC3542186/ /pubmed/22913517 http://dx.doi.org/10.1186/1471-2105-13-212 Text en Copyright ©2012 Wu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wu, Dingfeng Huang, Qi Zhang, Yida Zhang, Qingchen Liu, Qi Gao, Jun Cao, Zhiwei Zhu, Ruixin Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title | Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title_full | Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title_fullStr | Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title_full_unstemmed | Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title_short | Screening of selective histone deacetylase inhibitors by proteochemometric modeling |
title_sort | screening of selective histone deacetylase inhibitors by proteochemometric modeling |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/ https://www.ncbi.nlm.nih.gov/pubmed/22913517 http://dx.doi.org/10.1186/1471-2105-13-212 |
work_keys_str_mv | AT wudingfeng screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT huangqi screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT zhangyida screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT zhangqingchen screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT liuqi screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT gaojun screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT caozhiwei screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling AT zhuruixin screeningofselectivehistonedeacetylaseinhibitorsbyproteochemometricmodeling |